More recently, a first-in-human study of an exosome-based nanoplatform for Ldlr mRNA delivery is currently in phase I clinical trials (NCT05043181), promising to treat HoFH patients (Table 1). Here, LDLR is linked to homozygous familial hypercholesterolemia.